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Abstract 1 
BACKGROUND: Kisspeptin is a critical hypothalamic regulator of reproductive function.  2 
Chronic kisspeptin administration causes profound tachyphylaxis in male monkeys and in 3 
women with functional hypothalamic amenorrhea (HA). The pharmacological effects of 4 
chronic kisspeptin exposure in healthy women with normal menstrual cycles have not been 5 
studied previously. 6 
AIM: To determine the effects of follicular phase kisspeptin-54 treatment on menstrual 7 
cyclicity in healthy women. 8 
METHODS: We performed a prospective, single-blinded, one-way crossover study. Healthy 9 
women received twice-daily subcutaneous injections of kisspeptin (6.4nmol/kg) or 0.9% 10 
saline during menstrual days 7-14 (N=5 per treatment arm). Serial assessments of basal 11 
reproductive hormones, ultrasound parameters, luteinising hormone (LH) pulsatility, and 12 
acute sensitivity to GnRH and kisspeptin-54 injection were performed. 13 
RESULTS: Menstrual cyclicity persisted in all women following follicular phase kisspeptin-14 
54 treatment. Chronic exposure to kisspeptin-54 did not abolish acute stimulation of LH 15 
following injection of kisspeptin-54 or GnRH. In addition, kisspeptin-54 treatment was 16 
associated with a shorter mean length of menstrual cycle (mean length of menstrual cycle in 17 
days: saline 28.6±1.4 vs. kisspeptin 26.8±3.1, P<0.01), advanced the onset of highest recorded 18 
serum LH (mean menstrual day of highest LH: saline 15.2 ± 1.3 vs. kisspeptin 13.0±1.9, 19 
P<0.05), and advanced the onset of the luteal phase (mean menstrual day of progesterone 20 
increase: saline 18.0±2.1 vs. kisspeptin 15.8±0.9, P<0.05).  21 
CONCLUSION: Our data suggest that exogenous kisspeptin-54 does not abolish menstrual 22 
cyclicity in healthy women. Further work is needed to determine if kisspeptin could be used 23 
to treat certain anovulatory disorders. 24 
25 
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Introduction 1 
The kisspeptins are a group of arginine-phenylalanine (RF) amide peptides encoded by the 2 
KISS1 gene, which are endogenous ligands for the kisspeptin receptor (KISS1R)1-4. KISS1 and 3 
KISS1R are expressed predominantly in the hypothalamus, pituitary and placenta3,5-7. 4 
Kisspeptin signalling exerts powerful effects on the mammalian reproductive system. Mice 5 
and humans lacking kisspeptin or the kisspeptin receptor fail to undergo puberty and are 6 
infertile8-10. Central or peripheral administration of kisspeptin induces gonadotrophin and sex 7 
steroid release in all mammalian species investigated, including rats11-13, mice14,15, monkeys16 8 
and sheep17,18.  9 
Administration of kisspeptin-54 or kisspeptin-10 acutely stimulates gonadotrophin secretion 10 
in healthy male19-22 and female volunteers23,24, and  women with functional HA (hypothalamic 11 
amenorrhea)25,26. However, twice-daily subcutaneous administration of kisspeptin-54 to 12 
women with HA causes profound tachyphylaxis within 24h of commencing treatment25. 13 
Furthermore continuous intravenous infusion of kisspeptin-10 to monkeys is associated with 14 
tachyphylaxis within 3h of commencing administration16. It has therefore been assumed that 15 
chronic treatment with kisspeptin-54 in healthy women may have limited therapeutic potential 16 
as a stimulator of human reproductive activity, due to tachyphylaxis observed following 17 
chronic administration in primates and women with HA. However, this hypothesis has not 18 
been tested previously. 19 
In this study we aimed to determine whether chronic exogenous kisspeptin was sufficient to 20 
alter menstrual cyclicity, using the exact dose previously demonstrated to cause tachyphylaxis 21 
within 24h in women with HA (6.4nmol/kg)25,26. We performed a single-blinded placebo-22 
controlled one-way crossover study to determine the effects of twice-daily administration of 23 
kisspeptin for 7 days on the menstrual cycle in healthy human female subjects with regular 24 
menstrual cycles.  25 
26 
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Methods 1 
Subjects 2 
Ethical approval was granted by the Hammersmith and Queen Charlotte’s and Chelsea 3 
Hospitals Research Ethics Committee (registration number: 05/Q0406/142). Written informed 4 
consent was obtained from all subjects. This study was performed in accordance with the 5 
Declaration of Helsinki. Five healthy female subjects with regular menstrual cycles were 6 
recruited through advertisements placed in local newspapers (age in years: 31.6±2.6, range 7 
24-37; weight in kg: 60.4±2.5, range 50.4-63.8) as described previously22,23  8 
 9 
Protocol 10 
A single-blinded, placebo-controlled, one-way crossover design study of ten menstrual cycles 11 
was performed (Figure 1). During month 1 of the study protocol, five healthy female subjects 12 
self-administered twice-daily subcutaneous saline injections between days 7 and 14 of their 13 
menstrual cycle (see Subject Characteristics in Supplemental Table 1).  During month 2 of the 14 
study protocol, the same five healthy female subjects self-administered twice-daily 15 
subcutaneous kisspeptin-54 injections (6.4nmol/kg; equivalent to 37mcg/kg19) between days 7 16 
and 14 of their menstrual cycle; (see Supplemental Methods for kisspeptin-54 peptide 17 
synthesis and testing). Day 1 of each month was defined as the first day of menstrual bleeding.  18 
Kisspeptin injections: All subjects were trained in self-administration of subcutaneous 19 
injections by an investigator at the start of the study protocol. At the beginning of each week 20 
when injections were to be performed, a box containing unlabelled vials of freeze-dried saline 21 
(month 1) or vials of freeze-dried kisspeptin-54 (month 2), alcohol wipes, saline ampoules for 22 
reconstitution of freeze-dried vial contents, 0.5ml insulin syringes with needles, and needle 23 
disposal bins was given to each subject. For injection, vial contents were reconstituted in 24 
0.5ml of 0.9% saline. A 0.5ml insulin syringe was then used to inject saline alone (month 1) 25 
or 6.4nmol/kg of kisspeptin-54 (month 2) into the lower anterior abdominal region 26 
subcutaneously. This kisspeptin-54 dose was the same used in our previous work in healthy 27 
 6
women and women with HA25,26. Volunteers were instructed to prepare and perform 1 
injections in the morning after breakfast (unless attending for a study in which case it was 2 
done by the volunteer at time=0 of the study) and in the evening before bed. The volume of 3 
the saline or kisspeptin injections was identical. Subjects were instructed to refrigerate vials 4 
stored at home. Prior to commencing study visits, injection sites were inspected, and numbers 5 
of returned vials, insulin syringes, and saline or kisspeptin vials were counted in order to 6 
monitor compliance. Plasma kisspeptin immunoreactivity (-IR) was also assessed throughout 7 
the study protocol to confirm compliance. 8 
 9 
Baseline period: During menstrual days 1 to 6 of each month of the study protocol, pituitary 10 
responsiveness was assessed by a Gonadotrophin-Releasing Hormone (GnRH) test (see 11 
Supplemental Methods for protocol), and baseline reproductive hormones and ultrasound 12 
markers were measured. The collection, processing and analysis of blood samples are detailed 13 
in supplemental methods. The baseline period also allowed the acclimatisation of subjects to 14 
study conditions. No injections were administered during this period.  15 
Treatment period: During menstrual days 7 to 14 of each month of the study protocol, 16 
subjects self-administered twice-daily, single-blinded subcutaneous injections of saline 17 
(month 1 of study protocol) or kisspeptin-54 (month 2 of study protocol) as above.  18 
Post-treatment period: During menstrual days 15 to 28 of each month of the study protocol, 19 
subjects underwent a post-treatment observation period, in order to assess pituitary 20 
responsiveness (GnRH test), and measure circulating reproductive hormones and ultrasound 21 
markers. No injections were administered during this period.  22 
 23 
4 hour blood sampling post-injection of saline or kisspeptin: All subjects underwent blood 24 
sampling during the 4 hour period immediately following the first injection of the saline (day 25 
7, month 1) or kisspeptin-54 (day 7, month 2) treatment period in order to confirm that 26 
kisspeptin-54 acutely stimulated LH release as previously shown in healthy women23.  Saline 27 
or kisspeptin-54 6.4nmol/kg was subcutaneously administered at 0 minutes by the subject, 28 
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and blood was sampled for serum LH, FSH, estradiol, and plasma kisspeptin-IR at -30, 0, 10, 1 
20, 40, 60, 90, 120, 150, 180, 210 and 240 minutes. 2 
 3 
8 hour blood sampling for assessments of LH pulsatility: Subjects underwent three 4 
assessments of LH pulsatility during month 1 and month 2 of the study protocol. Baseline 5 
assessment of LH pulsatility was performed on menstrual day 6 (1 day prior to commencing 6 
injections). LH pulsatility was also assessed following injection of saline or kisspeptin-54 on 7 
menstrual days 11 and 14. The saline or kisspeptin-54 was reconstituted using one of the vials 8 
given to each subject at the beginning of the treatment period for home storage.  Blood was 9 
sampled every 10 minutes. Studies commenced between 0800h and 0900h. 10 
 11 
Assessment of pituitary sensitivity before and after injections of saline or kisspeptin: Subjects 12 
each underwent two GnRH tests during month 1 and month 2 of the study protocol (see 13 
Supplemental Methods for protocol). A baseline GnRH test was performed on menstrual day 14 
1 and was repeated in each subject 24 hours after final saline or kisspeptin injection 15 
(menstrual day 15). 16 
 17 
Basal measurement of reproductive hormones: Basal measurements of serum LH, FSH, 18 
estradiol, progesterone, and plasma kisspeptin IR were taken from subjects during days 1, 6, 7, 19 
11, 14, 15, 18, 21 and 28 during month 1 and month 2 of the study protocol. On days 7, 11 20 
and 14 the basal blood sample was taken before the morning injection.  21 
 22 
Ultrasound scans. Trans-abdominal ultrasound scans were performed on days 1, 7, 15, 18, 21 23 
and 28 during month 1 and month 2 of the study protocol. Trans-vaginal scans were not used 24 
to minimise discomfort to volunteers during repeated examinations. The ultrasonographer was 25 
blinded to treatment for all subjects. During each scan the following parameters were 26 
measured: endometrial thickness in millimetres (mm); mean ovarian volume in cubic 27 
centimetres (cm3); mean follicle number; maximum diameter of largest follicle in each ovary 28 
 8
(mm). Ovulation was defined as a rise in serum progesterone >10nmol/l together with 1 
suggestive radiological features (visualisation of a dominant follicle with subsequent 2 
appearance of a pre-ovulatory follicle and/or corpus luteum). 3 
 4 
Data analysis:  5 
Investigators performing the clinical studies were blinded to results until all subjects had 6 
completed the study protocol. JDV used an established, blinded deconvolution method with 7 
93% sensitivity and specificity27 to identify LH pulses, and calculate the secretory mass of LH 8 
pulses (integral of LH secretion over time during a secretory burst normalised per liter of 9 
distribution volume). Cumulative levels of basal, pulsatile and total (basal + pulsatile) LH 10 
secretion were also estimated during each study. Data are presented as mean±standard error of 11 
mean (SEM). Kisspeptin-IR data was log-transformed to normalise data prior to data analysis. 12 
All other analyses included data series, the majority of which had normal distributions 13 
assessed using the Komogorov-Smirnov test with Dallal-Wilkinson-Lillie analysis. Hormone 14 
profiles during 4 hour blood sampling studies were analysed using repeated measures 2-way 15 
ANOVA with Bonferonni post hoc correction. Pairs of means were analysed using the 16 
unpaired two-tailed t-test. Multiple means were compared using one-way ANOVA with 17 
Bonferonni’s Multiple Comparison Test. In all cases, P<0.05 was considered statistically 18 
significant. 19 
20 
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Results 1 
Acute effects of saline or kisspeptin-54injection on plasma kisspeptin at the commencement, 2 
mid-point and end of twice-daily administration in healthy women:  3 
(a) Acute changes in plasma kisspeptin-IR following injection of saline or kisspeptin-54: 4 
Plasma kisspeptin was unchanged at approximately 10pmol/l following injection of saline on 5 
the first (Figure 2A), fourth (Figure 2B) and final (seventh; Figure 2C) days of twice-daily 6 
administration. Kisspeptin-54 injection acutely elevated plasma kisspeptin-IR on the first day 7 
of administration, with peak mean kisspeptin-IR levels of 2421±392pmol/l at 45min post 8 
injection (P<0.001 vs. saline) (Figure 2A). Similar elevations of kisspeptin-IR were observed 9 
following injection of kisspeptin on the fourth and last injection days (Figures 2B-C). 10 
(b) Plasma kisspeptin-IR pre-injection of saline or kisspeptin-54: In subjects receiving saline, 11 
plasma kisspeptin-IR measured prior to the morning saline injection remained approximately 12 
10pmol/l throughout the study protocol (Figure 2D). In subjects receiving kisspeptin 13 
injections, plasma kisspeptin-IR was not elevated on menstrual days 1, 6 or 7 since these 14 
blood samples were taken prior to the first kisspeptin-54 injection. Plasma kisspeptin-IR was 15 
elevated on menstrual days 11 and 14 (during the twice daily kisspeptin treatment period but 16 
just prior to the morning kisspeptin injection), which suggested compliance with kisspeptin 17 
injection the previous evening. As expected, plasma kisspeptin-IR was not elevated on the 18 
morning of day 15, since it was approximately 24h following final kisspeptin-54 injection. 19 
Furthermore plasma kisspeptin-IR remained <10pmol/l on days 18-28 of the study protocol 20 
(Figure 1D).  21 
 22 
Acute effects of saline or kisspeptin-54 injection on serum reproductive hormones at the 23 
commencement, mid-point and end of twice-daily administration in healthy women:  24 
(a) Commencement of treatment period (menstrual day 7): Saline injection did not change 25 
serum LH levels when compared with baseline (Figure 3A, baseline LH 5.20±0.64IU/L). 26 
Kisspeptin-54 injection acutely increased serum LH levels in subjects when compared with 27 
saline (Figure 3A, P<0.05 at time-points 180 min to 210min, baseline LH 5.68±0.98IU/L). 28 
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The mean maximal increase in LH from baseline after kisspeptin injection was observed at 1 
240 minutes, and was 8.6±3.4IU/l above baseline.  2 
(b) Mid-point of treatment period (menstrual day 11): Saline injection did not change serum 3 
LH or FSH compared with baseline (Figure 3B, baseline LH 5.74±1.45IU/L). Kisspeptin-54 4 
injection acutely increased serum LH levels in subjects when compared with saline (Figure 5 
3B, P<0.01 at 210min, and P<0.05 at 220 to 240min, baseline LH 9.41±4.89IU/L). The mean 6 
maximal increase in LH from baseline after kisspeptin injection was observed at 240min, and 7 
was 8.3±2.4IU/l above baseline. 8 
(c) End of treatment period (menstrual day 14): Saline injection did not change serum LH or 9 
FSH compared with baseline (Figure 3C, baseline LH 17.79±9.69IU/L).  The mean maximal 10 
increase in LH from baseline after kisspeptin injection was observed at 220min, and was 11 
12.7±8.1IU/l above baseline (baseline LH 6.01±1.60IU/L). Kisspeptin-54 injection showed a 12 
trend towards stimulating serum LH but this did not reach statistical significance compared 13 
with saline. During days 7, 11 and 14 of the treatment period, total LH secretion was 14 
increased significantly following kisspeptin-54 when compared with saline (P<0.01 using 2-15 
way ANOVA) (Figure 3D).  16 
 17 
Effects of twice-daily saline or kisspeptin injections on length of the menstrual cycle and 18 
biochemical markers of reproductive activity in healthy women 19 
(a) Length of menstrual cycle: Subjects had the same menstrual cycle length prior to 20 
commencing the study when compared with menstrual cycle length during saline 21 
administration (mean menstrual cycle length in days: 28.6±1.1, prior to study commencement; 22 
28.6±1.4, saline month; P=1.00). However all subjects had a shorter menstrual cycle (by 23 
approximately 2 days) during kisspeptin-54 treatment when compared with saline (mean 24 
length of menstrual cycle in days: saline 28.6±1.4 vs. kisspeptin 26.8±3.1, P<0.01) (Figure 25 
4A). 26 
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(b) Timing of peak serum LH: During kisspeptin-54 treatment observed peak levels of serum 1 
LH and estradiol, but not FSH, were earlier during the menstrual cycle when compared with 2 
the saline group (Figures 4B-D). Furthermore the menstrual day of highest recorded serum 3 
LH was approximately 2 days earlier during kisspeptin-54 treatment when compared with 4 
saline treatment (mean menstrual day of highest recorded serum LH: saline 15.2±1.3 vs. 5 
kisspeptin 13.0±1.9, P<0.05) (Figure 4E).  6 
(c) Timing of luteal phase of menstrual cycle: We examined the onset of the luteal phase 7 
which is characterised by release of a mature oocyte from the ovary and secretion of 8 
progesterone by the residual corpus luteum. During kisspeptin-54 treatment, levels of serum 9 
progesterone became elevated >10nmol/L earlier during the menstrual cycle when compared 10 
with the saline group (Figure 4F). The menstrual day of onset of luteal phase (defined as 11 
beginning when serum progesterone was elevated >10nmol/l) was approximately 2 days 12 
earlier during kisspeptin-54 treatment when compared with saline treatment (mean menstrual 13 
day of serum progesterone increase >10nmol/l: saline 18.0±2.1 vs. kisspeptin 15.8±0.9, 14 
P<0.05) (Figure 4G).  15 
 16 
Effects of twice-daily saline or kisspeptin injections on radiological markers of reproductive 17 
activity in healthy women 18 
A corpus luteum, indicating recent ovulation, was observed in all women following 19 
kisspeptin-54 treatment, and in 3/5 women following saline treatment. Elevated serum 20 
progesterone (>10nmol/l) was observed in all subjects receiving saline or kisspeptin-54 21 
treatment. Immediately following 7 days of kisspeptin-54 treatment (on menstrual day 15), 22 
the mean diameter of the largest follicle seen during ultrasonography was significantly higher 23 
when compared with women during saline treatment (mean diameter of largest follicle in mm: 24 
saline 10.0±2.2 vs. kisspeptin 15.5±1.2, P<0.05) (Figure 5A). No significant differences in 25 
number of follicles or endometrial thickness were observed during kisspeptin-54 treatment 26 
when compared with saline (Figure 5B,C). 27 
 28 
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Effects of twice-daily saline or kisspeptin on LH pulsatility in healthy women  1 
LH pulsatility was determined immediately prior to commencing saline or kisspeptin-54 2 
treatment (menstrual day 6 of study protocol), and during saline or kisspeptin-54 treatment 3 
(menstrual days 11 and 14 of study protocol). Mean secretory mass was slightly lower before 4 
kisspeptin-54 treatment when compared with saline treatment (mean secretory mass in IU/L: 5 
saline 5.9±0.5 vs. kisspeptin 4.1±0.4, P<0.01) (Figure 6A). Despite this, mean secretory mass 6 
was increased significantly during menstrual day 11 (4th day of treatment) during kisspeptin-7 
54 treatment when compared with the saline treatment (mean secretory mass in IU/L: saline 8 
3.4±0.4 vs. kisspeptin 14.5±3.6, P<0.01). On the last day of treatment (menstrual day 14) no 9 
significant differences in secretory mass were observed between saline or kisspeptin-54 10 
treatment. No significant differences in pulse rate were observed between saline and 11 
kisspeptin-54 treatment (Figure 6B). Pulsatile LH secretion was increased significantly during 12 
menstrual day 11 (4th day of treatment) in the kisspeptin-54 group when compared with the 13 
saline group (mean secretory mass in IU/L: saline 17.9±3.6 vs. kisspeptin 78.2±22.8, P<0.05) 14 
(Figure 6C). However basal and total LH secretion were not significantly different between 15 
groups (Figure 6 D-E).  16 
 17 
Assessment of pituitary sensitivity before and after injections of saline or kisspeptin: 18 
We examined sensitivity of all healthy female subjects to intravenous GnRH, both 6 days 19 
before (menstrual day 1 of study protocol) and 24h after saline or kisspeptin treatment 20 
(menstrual day 15 of study protocol). On menstrual day 1, no significant difference in 21 
pituitary sensitivity was observed following GnRH administration between subjects prior to 22 
commencing saline of kisspeptin treatment (mean maximal LH increase during first 2h post-23 
GnRH injection in IU/L: 13.1±1.1; pre-saline, 13.4±1.1 pre-kisspeptin-54; P=ns) 24 
(Supplemental Figure 1A). Furthermore 24h following cessation of twice-daily saline or 25 
kisspeptin-54 injections, no significant difference in pituitary sensitivity was observed 26 
following GnRH administration between saline or kisspeptin-54 treatment (mean maximal LH 27 
 13
increase during first 2 hours post-GnRH injection in IU/L: 39.9±8.9; post-saline, 41.0±16.4 1 
post-kisspeptin-54; P = ns) (Supplemental Figure 1B). 2 
The expected physiological increase in pituitary sensitivity to GnRH during menstrual day 15 3 
versus menstrual day 132 was observed in healthy female subjects, whether receiving saline or 4 
kisspeptin treatment (Supplemental Figure 1C).  5 
 14
Discussion 1 
Genetic studies demonstrate that kisspeptin peptides are necessary for pubertal maturation in 2 
humans8-10. We and other investigators have recently demonstrated that exogenous kisspeptin 3 
acutely stimulates gonadotrophin secretion in women23-26. However the pharmacological 4 
effects of chronic kisspeptin exposure to healthy women with regular menstrual cycles have 5 
not been studied previously. Chronic kisspeptin administration causes profound tachyphylaxis 6 
in male monkeys and in women in functional HA16,25,26. We present novel data suggesting that 7 
menstrual cyclicity persists in healthy women following twice-daily kisspeptin-54 treatment 8 
during the follicular phase of the menstrual cycle.  9 
In the current study, kisspeptin treatment was associated with an advanced timing of serum 10 
progesterone increase, and onset of menstrual bleeding by approximately 2 days when 11 
compared with saline. Animal studies demonstrate that kisspeptin stimulates gonadotrophin 12 
secretion in a GnRH-dependent manner, since its action is abolished by GnRH antagonist14. 13 
Exogenous GnRH is sufficient to trigger ovulation28. Further studies with daily follicle 14 
morphology assessment, and daily serum LH measurement would be required to confirm our 15 
findings. However our study data raise the possibility that kisspeptin-54 administration may 16 
advance the onset of ovulation in healthy women by stimulating endogenous hypothalamic 17 
GnRH secretion. In addition to stimulating GnRH, kisspeptin itself is implicated in generation 18 
of the LH surge needed for ovulation. In rodents, a subpopulation of hypothalamic 19 
anteroventral periventricular nucleus (AVPV) kisspeptin neurons are implicated in generating 20 
the LH surge needed for ovulation29, and are positively rather than negatively regulated by 21 
estradiol30. Central administration of a monoclonal antibody to kisspeptin is sufficient to 22 
block ovulation in rats31. Furthermore, administration of kisspeptin-10 has been shown to 23 
stimulate ovulation in the musk shrew32, rat33 and sheep17. Humans have no anatomical 24 
equivalent of the AVPV. Nevertheless, it is possible that exogenous kisspeptin-54 may have 25 
advanced the onset of luteal phase in our female subjects by increasing kisspeptin signalling 26 
in a subpopulation of hypothalamic kisspeptin neurons which stimulate the LH surge. Several 27 
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lines of evidence suggest that in humans unlike in lower species, a change in pituitary 1 
responsiveness to GnRH rather than an actual GnRH surge is responsible for the LH surge34,35. 2 
It is therefore possible that kisspeptin-54 advances ovulation in women by increasing the 3 
prevailing levels of estradiol, which are needed to trigger the LH surge at a pituitary level.  4 
Chronic kisspeptin administration has also been implicated as a potential novel therapy for 5 
inhibiting reproductive hormone secretion in contraception or the treatment of hormone 6 
sensitive cancer; our data suggest that kisspeptin-54 may have limited therapeutic potential in 7 
this regard, at least in women at the dose of kisspeptin tested. However our observation that 8 
kisspeptin may advance the menstrual cycle, raises the possibility that women with certain 9 
forms of infertility could be treated with kisspeptin. A recent study suggests that kisspeptin is 10 
sufficient to restore ovulation in a mouse model of anovulatory hyperprolactinaemia36. 11 
Further studies are required to determine if kisspeptin-54 treatment could be used to stimulate 12 
ovulation in women with anovulatory reproductive disorders other than HA.  13 
Traditional ovulatory drugs such as clomiphene citrate have low pregnancy rates37,38. 14 
Although efficacious, in vitro fertilisation (IVF) confers a risk of ovarian hyperstimulation39. 15 
Kisspeptin acts by stimulating endogenous, rather than pharmacological, levels of 16 
reproductive hormone secretion. Kisspeptin might therefore offer a fertility treatment with 17 
lower risk of OHSS when compared with IVF. 18 
Comparison of our data with other clinical studies of kisspeptin administration is complicated 19 
by the investigation of its two peptide forms (kisspeptin-54 and -10), and sexual dimorphism 20 
of the effects of kisspeptin-10; intravenous bolus administration consistently stimulates LH 21 
men20,21,22, but women are much less sensitive to the effects of kisspeptin-10 during the 22 
follicular phase of menstrual cycle when compared with the preovulatory phase22,24. Although 23 
kisspeptin-54 stimulates LH in both sexes, its effects have never been compared directly 24 
between men and women19,23.  Consistent with our findings in healthy women, George et al. 25 
recently observed that 22.5 hour intravenous infusion of the shorter form of kisspeptin, 26 
kisspeptin-10, stimulates LH secretion without apparent tachyphylaxis in healthy men21. 27 
However in contrast to the current findings, twice daily kisspeptin-54 treatment has been 28 
 16
shown to rapidly cause tachyphylaxis in women with HA. Women with HA are acutely 4-fold 1 
more sensitive to the effects of kisspeptin-54 when compared with healthy women in the 2 
follicular phase of their menstrual cycle. A higher dose of kisspeptin-54 may therefore be 3 
necessary to achieve tachyphylaxis in healthy female volunteers23,25. Nevertheless, our data 4 
suggest that menstrual cyclicity is able to persist in healthy women using the currently tested 5 
regimen of follicular phase kisspeptin-54 treatment. Preliminary data has emerged suggesting 6 
that chronic administration of a kisspeptin analogue causes tachyphylaxis in healthy men40. It 7 
would be interesting to determine if tachyphlyaxis to kisspeptin-54 is also sexually dimorphic, 8 
or dependent on the dose and precise form of kisspeptin receptor agonist administered. 9 
It is interesting to note that while intravenous bolus injection of the shorter kisspeptin 10 
fragment, kisspeptin-10, acutely stimulates LH secretion within an hour of administration, we 11 
observed that sc injection of kisspeptin-54 acutely stimulated peak LH secretion 3-4h 12 
following administration despite a rapid elevation of kisspeptin-IR within minutes of 13 
administration. Kisspeptin-54 is a much more potent stimulator of LH secretion when 14 
compared with kisspeptin-10; it might therefore take longer for kisspeptin-54 to stimulate 15 
higher levels of LH secretion. It is also possible that greater levels of estradiol stimulation 16 
following kisspeptin-54 when compared with kisspeptin-10, lead to ‘auto-priming’ of the 17 
pituitary to respond even more to stimulation by GnRH.  18 
It is interesting to appraise the evidence that exogenous kisspeptin stimulates basal and 19 
pulsatile GnRH secretion. Although kisspeptin stimulates rat pituitary gonadotrophin 20 
secretion in vitro41, animal studies using GnRH antagonists support the view that exogenous 21 
kisspeptin stimulates basal LH secretion through a GnRH-dependent mechanism42, which is 22 
possibly mediated through GnRH nerve terminals at the median eminence43. However it is 23 
less clear whether exogenous kisspeptin stimulates endogenous GnRH pulsatility. Sustained 24 
exposure to exogenous kisspeptin-10 or -54 stimulates pulsatile LH secretion for several 25 
hours in healthy men21, and patients with inactivating mutations of the NKB signalling 26 
pathway44. However since these studies merely measure LH pulsatility, it is not possible to 27 
exclude that effects reflect increasing circulating oestrogen and pituitary responsiveness to 28 
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unchanged, endogenous GnRH pulsatility. Chan and colleagues recently demonstrated that 1 
intravenous bolus kisspeptin-10 increased the time to the next endogenous LH pulse in 2 
healthy men20; this may represent the only current data suggesting that exogenous kisspeptin 3 
can directly modulate endogenous GnRH pulsatility in humans (by increasing the latency 4 
period to next LH/ GnRH pulse). 5 
It is important to recognise that the current study is based on observations within a small 6 
number of subjects, so may have insufficient statistical power to reveal subtle effects of 7 
kisspeptin-54 administration on menstrual cyclicity or LH pulsatility. Furthermore, 8 
gonadotrophin response to kisspeptin treatment is known to alter with the phase of menstrual 9 
cycle in healthy women23,24. A larger study is needed to confirm our findings and determine 10 
what factors influence the variability in response of subjects to kisspeptin treatment. It is 11 
possible that chronic kisspeptin-54 treatment might have effects which last beyond the 12 
treatment period. For this reason, we designed a one-way crossover protocol in which subjects 13 
self-administered saline during the first month followed by kisspeptin-54 during the second 14 
month. It therefore remains possible that an order effect might have contributed to our results. 15 
However it is noteworthy that LH pulse secretory mass was marginally lower at the start of 16 
the second month when compared with LH pulse secretory mass at the start of month one 17 
(when greater stress levels would be expected). Furthermore, subjects had the same menstrual 18 
cycle length prior to commencing the study when compared with menstrual cycle length 19 
during saline administration. We also recognise that although estradiol measurements were 20 
compared with placebo-controlled values, the automated platform assay used to analyse 21 
serum estradiol can cross-react with other steroids.  22 
Mean peak levels of LH during the menstrual cycle were lower during kisspeptin treatment 23 
when compared with saline treatment. We therefore cannot exclude that kisspeptin-54 24 
treatment caused partial tachyphylaxis in healthy female volunteers. Alternatively, the short 25 
baseline sampling period involving just two blood samples may have reduced our power to 26 
detect stimulation of LH following kisspeptin-54 injection on day 14. LH levels were highly 27 
variable during menstrual day 14; this may have been caused by some but not all subject 28 
 18
experiencing an LH surge, and by the potential effect of kisspeptin-54 to advance the onset of 1 
LH surge in subjects.  2 
It is noteworthy that all subjects had peak progesterone levels ≥ 21mmol/l following 3 
kisspeptin-54 treatment, which is highly suggestive of ovulation. Furthermore a corpus 4 
luteum was observed in all five subjects during the month of kisspeptin-54 treatment 5 
(Supplemental Table 2). Our data therefore suggest that all five subjects had ovulatory cycles 6 
during kisspeptin treatment. Further studies are required to determine if menstrual cycles 7 
during kisspeptin therapy have subtle physiological differences when compared with natural 8 
menstrual cycles, and to determine if anovulation is observed at a different frequency during 9 
kisspeptin treatment when compared with placebo treatment.   10 
In summary, our data have important pharmacological implications; menstrual cyclicity 11 
persists in healthy women during a treatment regime of kisspeptin-54 previously 12 
demonstrated to cause tachyphylaxis in women with HA. Furthermore, kisspeptin-54 13 
treatment is associated with an advanced timing of the luteal phase of menstrual cycle when 14 
compared with placebo. Further studies are required to determine if kisspeptin-54 therapy 15 
could have potential to treat patients with anovulatory reproductive disorders.    16 
 19
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Figure Legends 1 
Figure 1. Study protocol diagram. 2 
Five healthy women underwent a one-way crossover protocol. Twice-daily injections of 3 
saline and kisspeptin-54 were administered between days 7 and 14 during month 1 and 2 of 4 
the protocol, respectively. During each month of the protocol, subjects underwent a baseline 5 
GnRH test (day 1) and 8h blood sampling (day 6) prior to commencing injections. During the 6 
injection period (days 7-14), subjects underwent a 4h study (day 7) and two further 8h studies 7 
(days 11 and 14) immediately following injection of saline or kisspeptin-54. A GnRH test was 8 
performed 24h after cessation of saline or kisspeptin treatment (day 15). ‘USS’ denotes 9 
ultrasound examination and measurement of reproductive hormones. Day 1 was defined as 10 
the first day of menstrual bleeding.  11 
 12 
Figure 2. Acute changes in plasma kisspeptin levels in healthy women receiving twice-13 
daily injections of saline or kisspeptin-54. 14 
A-C: Time-profiles of plasma kisspeptin immunoreactivity (IR) following sc bolus injection 15 
of saline or kisspeptin-54 at time 0min on menstrual days 7 (A), 11 (B) and 14 (C) of the 16 
study protocol. D: Bar graph comparing mean pre-injection kisspeptin IR following saline or 17 
kisspeptin-54 throughout the study protocol. All subjects commenced twice-daily treatment 18 
with saline or kisspeptin-54 on the morning of menstrual day 7 following their basal blood 19 
sample, and finished treatment on the morning of day 14. Data are presented as mean±SEM. *, 20 
P<0.05; **, P<0.01. 21 
 22 
Figure 3. Acute changes in serum reproductive hormones in healthy women receiving 23 
twice-daily injections of saline or kisspeptin-54. 24 
A-C: Acute increases in serum LH following sc bolus injection of saline or kisspeptin-54 at 25 
time 0min on menstrual days 7 (A), 11 (B) and 14 (C) of the study protocol. All subjects 26 
underwent treatment during menstrual days 7 and 14 with twice-daily sc bolus of saline or 27 
kisspeptin-54 injections. D: Summary bar graph comparing mean area under curve (AUC) LH 28 
 26
increase following saline or kisspeptin-54, on days 7, 11 and 14 of the study protocol. Data 1 
are presented as mean±SEM. *, P<0.05; **, P<0.01. 2 
 3 
Figure 4. Levels of serum reproductive hormones throughout the menstrual cycle in 4 
healthy women receiving twice-daily injections of saline or kisspeptin-54. 5 
A: Comparison of cycle length in individual healthy women undergoing twice-daily sc bolus 6 
injections of saline or kisspeptin-54 between menstrual days 7 and 14 of the study protocol. 7 
B-D: Levels of serum LH (B), FSH (C) and estradiol (D) during the menstrual cycle in 8 
healthy women undergoing twice-daily sc bolus injections of saline or kisspeptin-54  between 9 
menstrual days 7 and 14. E: Comparison of peak serum LH in individual healthy women 10 
undergoing twice-daily sc bolus injections of saline or kisspeptin-54 between menstrual days 11 
7 and 14 of the study protocol. F-G: Levels of serum progesterone (F), and comparison of 12 
menstrual day of onset of luteal phase (G) in individual healthy women undergoing twice-13 
daily sc bolus injections of saline or kisspeptin-54 between menstrual days 7 and 14 of the 14 
study protocol. The luteal phase of menstrual cycle was defined as beginning when serum 15 
progesterone was elevated >10nmol/l. *, P<0.05; **, P<0.01. Data are presented as 16 
mean±SEM. 17 
 18 
Figure 5. Changes in radiological markers during the menstrual cycle of healthy women 19 
receiving twice-daily injections of saline or kisspeptin-54. 20 
Mean values for diameter of largest ovarian follicle (A), number of ovarian follicles (B) and 21 
endometrial thickness (C) in healthy women undergoing twice-daily sc bolus injections of 22 
saline or kisspeptin-54 (6.4nmol/kg) between menstrual days 7 and 14.  Data are presented as 23 
mean±SEM. 24 
 25 
Figure 6. Changes in LH pulsatility during the menstrual cycle of healthy women 26 
receiving twice-daily injections of saline or kisspeptin-54. 27 
 27
All women underwent frequent blood sampling for 8h on menstrual days 6, 11 and 14 of the 1 
study protocol. Twice-daily sc bolus injections of saline or kisspeptin-54 (6.4nmol/kg) were 2 
self-administered between menstrual days 7 and 14. A-B: Mean values for secretory mass (A), 3 
and estimated pulses per 24h (B) are presented. C-E: Levels of pulsatile (C), basal (D) and 4 
total (E) LH secretion during each 8h sampling study are presented. Data are presented as 5 
mean±SEM.*, P<0.05; **, P<0.01. 6 
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Figure 6 
